India's Indigenous mpox detection RT-PCR kit gets manufacturing nod from CDSCO
New Delhi: A home-grown Indigenous RT-PCR testing kit to fight against Monkeypox has received manufacturing approval from the Central Drugs Standard Control Organization (CDSCO).
IMDX Monkeypox Detection RT-PCR Assay by Siemens Healthineers will be manufactured at the Company's molecular diagnostics manufacturing unit located in Vadodara, having a manufacturing capacity of 1 million reactions per annum.
The factory is all set to make the kits available. This is a significant achievement for our "Make in India" initiative and a critical advancement in the fight against the Monkeypox public health emergency, as per the release.
This is a significant achievement for our "Make in India" initiative and a critical advancement in the fight against the Monkeypox public health emergency.
The IMDX Monkeypox Detection RT-PCR Assay, a molecular diagnostic test targets two distinct regions in the viral genome, spanning both clade I and clade II variants of the virus. This ensures thorough detection across various viral strains, providing comprehensive results. Notably, this assay is platform-agnostic and seamlessly fits into existing lab workflows with standard PCR setups, eliminating the need for new instruments. The ability to use existing COVID testing infrastructure would enhance the efficiency.
According to the Company, the assay helps reduce the turnaround time for reporting with results available in just 40 minutes, significantly faster than traditional methods (which take 1-2 hours). Clinically validated by ICMR-National Institute of Virology, Pune, the assay boasts an impressive 100% sensitivity and specificity. IMDX Monkeypox RTPCR Assay kits adhere to Indian statutory guidelines and comply with the highest global standards.
Hariharan Subramanian, Managing Director, Siemens Healthcare Private Limited said, “The urgency for precise and accurate diagnostics couldn't be more crucial than now. By providing India with advanced assay kits tailored to combat Monkeypox, we are taking a proactive stance in battling this disease and prioritizing prompt and precise detection that can truly make a difference in saving lives. These kits are a testament to our focus on improving 'Access to Care' and these assay kits are a significant step toward that goal."
Read also: Working on Monkeypox vaccine: Serum Institute CEO
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.